Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus bevacizumab + lomustine versus lomustine in recurrent glioblastoma
NL-OMON27373Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Avastin, Avastin + lomustine and lomustine (3 arms). Primary endpoint: 9-month overall survival. Started Jan 2009; status: recruiting.
02
Drugs
bevacizumablomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON27373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27373.